Parabilis (PBLS) director lists Series F Preferred holdings convertible into 105,414 common shares

Rhea-AI Filing Summary

Parabilis Medicines, Inc. director Alexis Borisy filed an initial ownership report showing a direct holding of Series F Preferred Stock. Each share of this preferred stock is convertible into Common Stock on a 1 to 0.6498 basis at the holder’s option and has no expiration date. The filing notes that this preferred stock will automatically convert into 105,414 shares of Common Stock immediately prior to the closing of the company’s initial public offering and without any payment of additional consideration. The filing does not report any new purchase or sale, only the existing position.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Borisy Alexis

Role null

Type	Security	Shares	Price	Value
holding	Series F Preferred Stock	--	--	--

Holdings After Transaction: Series F Preferred Stock — 105,414 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Underlying common shares: 105,414 shares Conversion ratio: 1 to 0.6498 Exercise price: $0.0000 per share

3 metrics

Underlying common shares 105,414 shares Shares of Common Stock underlying Series F Preferred Stock

Conversion ratio 1 to 0.6498 Series F Preferred Stock to Common Stock conversion basis

Exercise price $0.0000 per share Conversion/exercise price for Series F Preferred Stock

Key Terms

Series F Preferred Stock, convertible into Common Stock, initial public offering, underlying security

4 terms

Series F Preferred Stock financial

"Each share of Series F Preferred Stock (the "Preferred Stock") is convertible"

Series F preferred stock is a class of company shares that gives holders priority over common shareholders for dividend payments and for getting money back if the company is sold or liquidated, much like a ticket that moves you to the front of the line. These shares often carry a fixed dividend and special rights—sometimes including conversion into common stock—so investors consider them when weighing income, downside protection and potential ownership dilution.

convertible into Common Stock financial

"is convertible into Common Stock on a 1 to 0.6498 basis at any time"

initial public offering financial

"immediately prior to the closing of the Issuer's initial public offering (the "IPO")"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

underlying security financial

"underlying_security_title": "Common Stock","underlying_security_shares": "105414.0000""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 06/12/2026 - 01:32 PM Accepted by SEC EDGAR 06/09/2026 - 09:03 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Borisy Alexis

(Last) (First) (Middle)

C/O PARABILIS MEDICINES, INC.

30 ACORN PARK DRIVE, 6TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02140

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/09/2026

3. Issuer Name and Ticker or Trading Symbol
Parabilis Medicines, Inc. [ PBLS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series F Preferred Stock	(1)	(1)	Common Stock	105,414	(1)	D

Explanation of Responses:

1. Each share of Series F Preferred Stock (the "Preferred Stock") is convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and will automatically convert into the number of shares shown in Column 3 immediately prior to the closing of the Issuer's initial public offering (the "IPO") and without payment of consideration. The Preferred Stock has no expiration date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Teresa Jurgensen, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What did Alexis Borisy report in the Parabilis (PBLS) Form 3 filing?

Alexis Borisy reported a direct holding of Series F Preferred Stock in Parabilis Medicines. This preferred stock is convertible into Common Stock and will automatically convert into 105,414 shares immediately before the company’s initial public offering, reflecting his pre-IPO equity position.

How many Parabilis (PBLS) common shares are underlying the reported preferred stock?

The Form 3 shows 105,414 underlying shares of Parabilis Common Stock. These shares result from the automatic conversion of the Series F Preferred Stock immediately prior to the company’s initial public offering, based on the stated 1 to 0.6498 conversion ratio.

What is the conversion ratio for Parabilis (PBLS) Series F Preferred Stock?

Each share of Parabilis Series F Preferred Stock is convertible into Common Stock on a 1 to 0.6498 basis. This means every preferred share turns into 0.6498 of a Common Share, and the preferred stock will convert automatically into the disclosed 105,414 common shares before the IPO.

Does the Parabilis (PBLS) Series F Preferred Stock reported in the Form 3 have an expiration date?

The Series F Preferred Stock reported in the Form 3 has no expiration date. It can be converted into Common Stock at any time at the holder’s option and will also automatically convert into 105,414 common shares immediately prior to the closing of the company’s initial public offering.

Does the Parabilis (PBLS) Form 3 show any insider buying or selling activity?

The Form 3 does not show any new insider buying or selling activity. It is an initial ownership report that lists Alexis Borisy’s existing holdings of Series F Preferred Stock and the 105,414 underlying common shares that will result from its automatic conversion before the IPO.